US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Articles published by Ceapro Inc.

News headline image
Aeterna Zentaris and Ceapro Complete Merger Transaction
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
News headline image
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
From Ceapro Inc.
Via GlobeNewswire
Tickers AEZS CRPOF TSX-V:CZO TSX:AEZS
News headline image
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Results of 2023 Shareholders’ Meeting
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Announces Grant of Stock Options
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO
News headline image
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
From Ceapro Inc.
Via GlobeNewswire
Tickers CRPOF TSX-V:CZO